The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

In the broader context, Eli Lilly’s Retatrutide shows stronger peak weight loss efficacy, with results nearing 25–30%, surpassing both CagriSema and Zepbound ... of the curve, that even ...

We obviously, rolled out Zepbound and this is -- we're just now ... that are now going from just weight loss, of course, we lose weight on the drug, the patients lose weight, does it convert ...

In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Even so, this relatively lean state had among the nation’s biggest surges last year in residents taking blockbuster weight-loss drugs ... such as Wegovy and Zepbound in 2024, a 255 percent ...

A Lilly-sponsored trial showed last month that Zepbound helped patients lose an average of 20.2% of their weight after 72 weeks, compared to 13.7% for a group treated with Wegovy. In December ...

high-demand drugs now known as "weight-loss" shots: Mounjaro, prescribed for diabetes, and Zepbound, for obesity. If you ask him what he's most excited about, it's not a daily, weekly, or even ...